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Introduction
Several converging lines of research suggest a relationship between bipolar disorder (BD) and epilepsy. Both conditions: are substantially heritable; follow an episodic course; can be chronic; and respond to anticonvulsant medications, all of
which suggest a common underlying pathophysiology 1. It is well recognized that mood disorders and epilepsy commonly co-occur. The psychiatric comorbidity of epilepsy has been well described, with mood disorders reported to
occur at much greater rates than the background prevalence (between 20-50%) 2. However, to date, much of the neuropsychiatric literature has focused on the study of unipolar depression with investigation into BD remaining limited. In
addition, there has been a distinct lack of studies exploring the assessment of epilepsy within a bipolar population. The present study looked to explore the comorbid relationship between BD and epilepsy. A primary aim of the study was
to assess the rate of self-reported epilepsy within a large, well-characterised sample of UK participants with a DSM-IV 3 diagnosis of BD. The secondary aim was to explore the relationship between self-reported epilepsy and the clinical
features and course of the bipolar illness.
Methods
Sample: This study utilised rich clinical data collected through the Bipolar Disorder Research Network (BDRN); a large, well-defined sample of UK participants (N>6000) with a DSM-IV diagnosis of bipolar disorder (bipolar I disorder, bipolar
II disorder, or schizoaffective bipolar type).
Assessment: BDRN participants were screened for a lifetime history of epilepsy/seizure disorder via a self-report questionnaire; a modified version of a brief screening instrument to identify individuals with epilepsy, designed by Ottman et
al (2010) 4. 1596 individuals completed the questionnaire and so were included in the study.
Data analysis: Demographic and lifetime bipolar clinical characteristics were compared between bipolar subjects with and without a self-reported history of epilepsy. Comparisons were made using Mann Whitney-U tests for continuous
variables 2x2 chi square tests for categorical variables. Variables significant within univariate analyses were entered into a logistic regression model to identify variables that best predicted the presence of epilepsy.
Conclusions
Results demonstrate an increased rate of epilepsy in the BD sample, compared to that reported in the general population (Ottman et al.,
2010). Multivariate analysis revealed an independent association of a history of suicide attempt with self-reported epilepsy within individuals
with BD, and this relationship did not appear to be explained by medication effects. Exploratory analysis (not presented here) revealed that
the association between epilepsy and suicide attempt within BD persisted even after adjusting for significantly associated bipolar and
epilepsy-related illness variables, as well as co-existing psychiatric and chronic medical conditions.
The current study highlights the importance of recognising and identifying comorbid epilepsy within individuals with BD, particularly given
the association of epilepsy with important illness outcomes, including increased suicidality. In addition, comorbid epilepsy within BD may
provide an attractive opportunity for subcategorising for future genetic studies, potentially facilitating the identification of shared
pathophysiological mechanisms.
Limitations: Self-reported definition of epilepsy. Due to the modest number of bipolar subjects with comorbid epilepsy and limited statistical
power, corrections were not routinely made for multiple testing.
BD+epilepsy
(n=127) 
BD-epilepsy
(n=1386)
P-value
Age at interview
Median (IQR)
Range
47.50 (15)
22-69
49 (17)
20-84
.632
Female, n (%) 86 (68.3%) 974 (70.3%) .635
Ever married, n (%) 112 (89.6%) 1146 (85.4%) .198
Post-secondary education, n 
(%)
78 (67.8) 969 (74.6%) .112
Systematic recruitment, n (%) 35 (28.1%) 360 (26.8%) .770
Family history of affective 
disorders, n (%)
92 (83.6%) 991 (86.2%) .464
DSM-IV diagnosis
BPI
BPII
SABP
85 (67.7%)
36 (28.3%)
5 (3.9%) 
940 (67.8%)
400 (28.9%)
46 (3.3%)
.928
Age of BD onset 
Median (IQR)
Range
20 (15)
9-51
21 (12)
5-64
.528
No. episodes mania
Median (IQR)
Range
5.1 (7.1)
1-100.1
5.1 (8)
1-300
.884
No. episodes depression
Median (IQR)
Range
10 (15.1)
0-100.1
8 (16)
0-150.1
.068
Psychotic features, n (%) 60 (64.4%) 733 (61.1%) .471
Rapid cycling, n (%) 30 (23.8%) 291 (21.1%) .475
Suicide attempt, n (%) 79 (64.2%) 631 (47.4%) .0003
History of psychiatric section, 
n (%)
41 (33.9%) 498 (37.6%) .417
GAS Mania
Median (IQR)
Range
39.50 (30)
10-60
35 (30)
5-65
.652
GAS Depression
Median (IQR)
Range
40 (14)
3-80
40 (15)
10-81
.155
BADDS Mania
Median (IQR)
Range
83 (5.03)
40-99
83 (5)
20-100
.500
BADDS Depression
Median (IQR)
Range
76 (22.6)
0-99
69.5 (22)
0-100
.194
BADDS Psychosis
Median (IQR)
Range
21 (18.25)
10-99
22 (19)
1-100
.876
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References
1Knott, S et al. (2015). Epilepsy & bipolar disorder. Epilepsy Behav, 52: 267-74. 
2Kanner, AM. (2003). Depression in epilepsy: prevalence, clinical semiology, pathogenic
mechanisms and treatment. Biol Psychiatry, 54: 388–398.
3American Psychiatric Association. (2000). Diagnostic and statistical manual of
mental disorders: DSM- IV (4th ed). Washington, DC: American Psychiatric Association
4Ottman, R et al. (2010). Validation of a brief screening instrument for the
ascertainment of epilepsy. Epilepsia, 51(2):191–197.
5Food and Drug Administration. (2008). Statistical Review and Evaluation:
Antiepileptic Drugs and Suicidality. US Department of Health and Human Services, FDA
Centre for Drug Evaluation and Research, Office of Translational Sciences, Office of
Biostatistics 2008.
BD+epilepsy
(n=127) 
BD-epilepsy
(n=1386)
P-value
Depression, n (%) 84 (84%) 983 (88.2%) .213
Schizophrenia, n (%) 3 (3.1%) 77 (6.9%) .154
Agoraphobia, n (%) 10 (10.1%) 51 (4.6%) .017
Panic disorder, n (%) 29 (29.6%) 175 (16.1%) .001
Phobias, n (%) 13 (13.6%) 63 (5.7%) .004
Generalised anxiety 
disorder, n (%) 67 (67.7%) 648 (59.1%) .096
Alcohol abuse, n (%) 18 (18.6%) 119 (10.6%) .017
Other substance abuse, n 
(%)
10 (10.2%) 45 (4%) .009 
Table 1. Demographic and bipolar illness variables according to the 
presence of comorbid epilepsy
Table 2. Psychiatric comorbidity within bipolar disorder according to 
the presence of comorbid epilepsy
A comparison of demographic characteristics, bipolar illness
variables, and psychiatric comorbidity between bipolar subjects with
and without a history of epilepsy is presented in tables 1 and 2.
Variables significant at the p<.05 level were included as explanatory
variables in a logistic regression model with absence or presence of
epilepsy as the dependent variable. Multivariate analysis revealed a
significant association between self-reported epilepsy and a history
of suicide attempt (OR: 1.790, 95% CI: 1.130-2.836, p=.013, Wald:
6.162, df=1). Within-group analysis revealed that this association did
not appear to be explained by medication effects, with rates of
lithium and antidepressant medication being similar between
epilepsy and no epilepsy groups. (figures 1 and 2).
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Figure 2.Rate of anti-
depressant use across 
bipolar subjects with and 
without comorbid epilepsy
Figure 1.Rate of lithium use 
across bipolar subjects with 
and without comorbid 
epilepsy
p=.175
p=.509
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In 2008, the Food and Drug Administration (FDA) issued a controversial alert
regarding a two-fold increased risk of suicidal thoughts and behaviour related to the
use of anti-epileptic drugs (AEDs). 5 Therefore, it is possible that the increased risk of
suicide attempt observed in bipolar subjects with comorbid epilepsy may be related
to the increased use of anti-epileptic medication.
An increased rate of AED use was observed within bipolar subjects with comorbid
epilepsy who had a history of suicide attempt compared to those without such
history, however this was not found to be statistically significant (46.3% vs. 34.2%,
p=.229).
